January 16, 2013 | It seems to be a season of shake ups in Big Pharma, and Derek Lowe is trading theories. Right now, the predominant ones include a split at
Pfizer, possibly leaving the small-molecule work without a home; and some possible changes at
AstraZeneca as the new CEO cleans house. In the Pipeline